– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today announced its third quarter 2021 financial results and provided a corporate update ...

Infinity Natural valued at $1.3 billion in debut as US energy IPOs rebound Infinity Natural Resources was valued at $1.30 billion after its shares jumped nearly 11% in their NYSE debut on Friday, ...

Infinity IPS is a financial services company. It provides mortgage due diligence and pre-fund and post-close quality control, and additional mortgage services including valuation, risk management, ...